Longevity Biomedical, Inc. (“Longevity” or “Longevity Biomedical”), a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring, and digital health solutions to increase human health span, and FutureTech II Acquisition Corp. (“FutureTech”) (NASDAQ: FTII), a publicly traded special purpose acquisition company (“SPAC”), announce that they have entered into a definitive business combination agreement (the “BCA”) on September 16, 2024. Upon the closing of the transaction pursuant to the BCA, the combined company (the “Combined Company”) will operate as Longevity Biomedical, Inc. and is expected to list on Nasdaq under the ticker symbol “LBIO.”
Source: https://www.globenewswire.com/news-release/2024/09/20/2949858/0/en/Longevity-Biomedical-Inc-and-FutureTech-II-Acquisition-Corp-Announce-Business-Combination-to-Create-Nasdaq-Listed-Biopharmaceutical-Company-Focused-on-Advancing-New-Technologies-to.html